{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T04:35:59Z","timestamp":1782189359734,"version":"3.54.5"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":["www.atsjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Patients with pulmonary hypertension due to interstitial lung disease (PH-ILD) have worse exercise capacity and survival than ILD patients without PH. Vasoreactivity with inhaled nitric oxide (NO) provides prognostic and therapeutic implications in pulmonary arterial hypertension, but little is known about its value in PH-ILD. We evaluated the pulmonary hemodynamic changes following inhaled NO and their association with outcomes in PH-ILD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We measured pulmonary hemodynamics in patients with PH-ILD who underwent inhaled NO administration during right heart catheterization. We recorded baseline clinical, echocardiographic, and pulmonary function testing measures, and investigated the use of inhaled treprostinil as well as the rate of hospitalization, death, and lung transplantation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In 120 patients (age 67\u2009\u00b1\u200911 years, 62% women), the administration of inhaled NO resulted in a median (IQR) decrease in mean pulmonary artery pressure (mPAP) of \u22123 (\u22125, \u22121) mmHg, P\u2009&amp;lt;\u20090.001, and pulmonary vascular resistance (PVR) of \u22120.8 (\u22121.8, \u22120.2) wood units (WU), P\u2009&amp;lt;\u20090.001. The % change in mPAP and PVR were \u22126.3 (\u221210.9, \u22121.8) % and \u221216.8 (\u221227.3, \u22123.3) %, respectively. Factors associated with the % drop in PVR included baseline PVR (r\u2009=\u20090.30, P\u2009&amp;lt;\u20090.001), cardiac output (r\u2009=\u2009\u22120.19, P\u2009=\u20090.04), and WHO functional class (r\u2009=\u20090.25, P\u2009=\u20090.01). The median (IQR) follow-up was 14.5 (7, 25) months. During this time, 40 (33%) patients died, 8 (7%) underwent lung transplantation, and 76 (63%) experienced either hospitalization due to respiratory failure, transplantation, or death. The % drop in mPAP and PVR during inhalation of NO had no significant impact on these outcomes and was not associated with clinical response to inhaled treprostinil measured by changes in six-minute walk distance (6MWD) and forced vital capacity (FVC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Inhaled NO caused a modest reduction in mPAP and PVR in patients with PH-ILD, but the acute hemodynamic response to inhaled NO was not associated with outcomes or response to inhaled treprostinil therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1513\/annalsats.202502-148oc","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T14:13:44Z","timestamp":1760537624000},"page":"345-355","update-policy":"https:\/\/doi.org\/10.1164\/crossmarkpolicies","source":"Crossref","is-referenced-by-count":2,"title":["Utility of inhaled nitric oxide vasoreactivity challenge in pulmonary hypertension associated with interstitial lung disease"],"prefix":"10.1093","volume":"23","author":[{"given":"Mamta S","family":"Chhabria","sequence":"first","affiliation":[{"name":"Department of Pulmonary and Critical Care Medicine, Mayo Clinic Health System , Eau Claire, WI,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaurav","family":"Manek","sequence":"additional","affiliation":[{"name":"Department of Pulmonary and Critical Care Medicine, MedStar Health , Clinton, MD,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Purnadeo N","family":"Persaud","sequence":"additional","affiliation":[{"name":"Division of Pulmonary Medicine, Integrated Hospital Care Institute, Cleveland Clinic , Cleveland, OH,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sravanthi","family":"Ennala","sequence":"additional","affiliation":[{"name":"Division of Pulmonary Medicine, Integrated Hospital Care Institute, Cleveland Clinic , Cleveland, OH,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bathmapriya","family":"Balakrishnan","sequence":"additional","affiliation":[{"name":"Division of Pulmonary Medicine, Integrated Hospital Care Institute, Cleveland Clinic , Cleveland, OH,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samar","family":"Farha","sequence":"additional","affiliation":[{"name":"Division of Pulmonary Medicine, Integrated Hospital Care Institute, Cleveland Clinic , Cleveland, OH,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriano R","family":"Tonelli","sequence":"additional","affiliation":[{"name":"Division of Pulmonary Medicine, Integrated Hospital Care Institute, Cleveland Clinic , Cleveland, OH,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,15]]},"reference":[{"key":"2026031709571826700_AnnalsATS.202502-AnnalsATS.202502-148OC-B1","doi-asserted-by":"publisher","first-page":"2200879","DOI":"10.1183\/13993003.00879-2022","article-title":"2022 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"61","author":"Humbert","year":"2023","journal-title":"Eur Respir J"},{"key":"2026031709571826700_AnnalsATS.202502-AnnalsATS.202502-148OC-B2","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1164\/rccm.201712-2405LE","article-title":"Disproportionate right ventricular dysfunction and poor survival in group 3 pulmonary hypertension","volume":"197","author":"Prins","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"2026031709571826700_AnnalsATS.202502-AnnalsATS.202502-148OC-B3","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1161\/CIRCRESAHA.121.319970","article-title":"Group 3 pulmonary hypertension: from bench to bedside","volume":"130","author":"Singh","year":"2022","journal-title":"Circ Res"},{"key":"2026031709571826700_AnnalsATS.202502-AnnalsATS.202502-148OC-B4","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1164\/rccm.202107-1766OC","article-title":"Efficacy of inhaled treprostinil on multiple disease progression events in patients with pulmonary hypertension due to parenchymal lung disease in the INCREASE trial","volume":"205","author":"Nathan","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2026031709571826700_AnnalsATS.202502-AnnalsATS.202502-148OC-B5","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1056\/NEJMoa2008470","article-title":"Inhaled treprostinil in pulmonary hypertension due to interstitial lung disease","volume":"384","author":"Waxman","year":"2021","journal-title":"N Engl J Med"},{"key":"2026031709571826700_AnnalsATS.202502-AnnalsATS.202502-148OC-B6","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.hlc.2022.09.005","article-title":"Acute vasoreactivity testing and outcomes in pulmonary arterial hypertension: a call for increased testing","volume":"32","author":"Chandrasekara","year":"2023","journal-title":"Heart Lung Circ"},{"key":"2026031709571826700_AnnalsATS.202502-AnnalsATS.202502-148OC-B7","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jjcc.2023.01.005","article-title":"Prognostic value of follow-up vasoreactivity test in pulmonary arterial hypertension","volume":"82","author":"Ishii","year":"2023","journal-title":"J Cardiol"},{"key":"2026031709571826700_AnnalsATS.202502-AnnalsATS.202502-148OC-B8","doi-asserted-by":"publisher","first-page":"250","DOI":"10.4103\/2045-8932.83449","article-title":"Vasoreactivity to inhaled nitric oxide with oxygen predicts long-term survival in pulmonary arterial hypertension","volume":"1","author":"Malhotra","year":"2011","journal-title":"Pulm Circ"},{"issue":"1:1801913.","key":"2026031709571826700_AnnalsATS.202502-AnnalsATS.202502-148OC-B9","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01913-2018","article-title":"Haemodynamic definitions and updated clinical classification of pulmonary hypertension","volume":"53","author":"Simonneau","year":"2019","journal-title":"Eur Respir J"},{"key":"2026031709571826700_AnnalsATS.202502-AnnalsATS.202502-148OC-B10","doi-asserted-by":"publisher","first-page":"20","DOI":"10.4103\/2045-8932.109911","article-title":"Nitric oxide deficiency in pulmonary hypertension: pathobiology and implications for therapy","volume":"3","author":"Tonelli","year":"2013","journal-title":"Pulm Circ"},{"key":"2026031709571826700_AnnalsATS.202502-AnnalsATS.202502-148OC-B11","first-page":"100015","article-title":"Methods to improve the yield of right heart catheterization in pulmonary hypertension","volume":"2","author":"Arunachalam","year":"2020","journal-title":"Respir Med X"},{"key":"2026031709571826700_AnnalsATS.202502-AnnalsATS.202502-148OC-B12","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1164\/rccm.200201-057OC","article-title":"Inhaled nitric oxide modifies left ventricular diastolic stress in the presence of vasoactive agents in heart failure","volume":"167","author":"Natori","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"2026031709571826700_AnnalsATS.202502-AnnalsATS.202502-148OC-B13","first-page":"323","article-title":"[Adaptation of the normal and ischemic heart to muscular exertion]","volume":"35","author":"Denolin","year":"1986","journal-title":"Ann Cardiol Angeiol (Paris)"},{"key":"2026031709571826700_AnnalsATS.202502-AnnalsATS.202502-148OC-B14","doi-asserted-by":"publisher","DOI":"10.3390\/ph16030418","article-title":"Pharmacology and emerging therapies for group 3 pulmonary hypertension due to chronic lung disease","volume":"16","author":"Gonzales","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"key":"2026031709571826700_AnnalsATS.202502-AnnalsATS.202502-148OC-B15","doi-asserted-by":"publisher","first-page":"1306032","DOI":"10.3389\/fmed.2023.1306032","article-title":"Evolution of pulmonary hypertension in interstitial lung disease: a journey through past, present, and future","volume":"10","author":"Arslan","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"2026031709571826700_AnnalsATS.202502-AnnalsATS.202502-148OC-B16","doi-asserted-by":"publisher","first-page":"00201","DOI":"10.1183\/23120541.00201-2024","article-title":"Vasoreactivity and inhaled treprostinil response in interstitial lung disease pulmonary hypertension","volume":"10","author":"Harder","year":"2024","journal-title":"ERJ Open Res"},{"key":"2026031709571826700_AnnalsATS.202502-AnnalsATS.202502-148OC-B17","doi-asserted-by":"publisher","first-page":"107835","DOI":"10.1016\/j.rmed.2024.107835","article-title":"Efficacy and determinants of response to inhaled treprostinil in pulmonary hypertension\u2014interstitial lung disease","volume":"234","author":"Balakrishnan","year":"2024","journal-title":"Respir Med"},{"key":"2026031709571826700_AnnalsATS.202502-AnnalsATS.202502-148OC-B18","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","article-title":"2015 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT)","volume":"37","author":"Galie","year":"2016","journal-title":"Eur Heart J"},{"key":"2026031709571826700_AnnalsATS.202502-AnnalsATS.202502-148OC-B19","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.rmed.2009.11.015","article-title":"Pulmonary vasodilator testing and use of calcium channel blockers in pulmonary arterial hypertension","volume":"104","author":"Tonelli","year":"2010","journal-title":"Respir Med"},{"key":"2026031709571826700_AnnalsATS.202502-AnnalsATS.202502-148OC-B20","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.chest.2022.04.002","article-title":"Impact of esophageal pressure measurement on pulmonary hypertension diagnosis in patients with obesity","volume":"162","author":"Khirfan","year":"2022","journal-title":"Chest"},{"key":"2026031709571826700_AnnalsATS.202502-AnnalsATS.202502-148OC-B21","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.amjcard.2023.09.032","article-title":"Can inhaled nitric oxide response predict tolerance to therapies and survival in patients with combined precapillary and postcapillary pulmonary hypertension?","volume":"207","author":"Krishtopaytis","year":"2023","journal-title":"Am J Cardiol"},{"key":"2026031709571826700_AnnalsATS.202502-AnnalsATS.202502-148OC-B22","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"61","author":"von Elm","year":"2008","journal-title":"J Clin Epidemiol"},{"key":"2026031709571826700_AnnalsATS.202502-AnnalsATS.202502-148OC-B23","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1378\/chest.10-0981","article-title":"Effect of balloon inflation volume on pulmonary artery occlusion pressure in patients with and without pulmonary hypertension","volume":"139","author":"Tonelli","year":"2011","journal-title":"Chest"},{"key":"2026031709571826700_AnnalsATS.202502-AnnalsATS.202502-148OC-B24","doi-asserted-by":"publisher","first-page":"911","DOI":"10.21037\/cdt-24-189","article-title":"Number of attempts and interventions to obtain a valid pulmonary artery wedge pressure","volume":"14","author":"Krishtopaytis","year":"2024","journal-title":"Cardiovasc Diagn Ther"},{"key":"2026031709571826700_AnnalsATS.202502-AnnalsATS.202502-148OC-B25","doi-asserted-by":"publisher","first-page":"693","DOI":"10.21037\/cdt-22-244","article-title":"Hemodynamic indices in pulmonary hypertension: a narrative review","volume":"12","author":"Manek","year":"2022","journal-title":"Cardiovasc Diagn Ther"},{"key":"2026031709571826700_AnnalsATS.202502-AnnalsATS.202502-148OC-B26","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s00408-019-00318-0","article-title":"Is there value in repeating inhaled nitric oxide vasoreactivity tests in patients with pulmonary arterial hypertension?","volume":"198","author":"Tooba","year":"2020","journal-title":"Lung"},{"key":"2026031709571826700_AnnalsATS.202502-AnnalsATS.202502-148OC-B27","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.\u00adamjcard.2004.09.006","article-title":"New predictors of outcome in idiopathic pulmonary arterial hypertension","volume":"95","author":"Kawut","year":"2005","journal-title":"Am J Cardiol"},{"key":"2026031709571826700_AnnalsATS.202502-AnnalsATS.202502-148OC-B28","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1161\/CIRCULATIONAHA.122.063821","article-title":"Positive vasoreactivity testing in pulmonary arterial hypertension: therapeutic consequences, treatment patterns, and outcomes in the modern management era","volume":"149","author":"Gerhardt","year":"2024","journal-title":"Circulation"},{"key":"2026031709571826700_AnnalsATS.202502-AnnalsATS.202502-148OC-B29","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.1161\/CIRCULATIONAHA.104.488486","article-title":"Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension","volume":"111","author":"Sitbon","year":"2005","journal-title":"Circulation"},{"key":"2026031709571826700_AnnalsATS.202502-AnnalsATS.202502-148OC-B30","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01324-2024","article-title":"Definition, classification and diagnosis of pulmonary hypertension","volume":"64","author":"Kovacs","year":"2024","journal-title":"Eur Respir J"},{"key":"2026031709571826700_AnnalsATS.202502-AnnalsATS.202502-148OC-B31","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.bcp.2012.03.012","article-title":"Binding and activity of the prostacyclin receptor (IP) agonists, treprostinil and iloprost, at human prostanoid receptors: treprostinil is a potent DP1 and EP2 agonist","volume":"84","author":"Whittle","year":"2012","journal-title":"Biochem Pharmacol"},{"key":"2026031709571826700_AnnalsATS.202502-AnnalsATS.202502-148OC-B32","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s00408-017-0081-7","article-title":"Inhaled treprostinil in pulmonary hypertension associated with lung disease","volume":"196","author":"Faria-Urbina","year":"2018","journal-title":"Lung"},{"key":"2026031709571826700_AnnalsATS.202502-AnnalsATS.202502-148OC-B33","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1016\/S2213-2600(21)00165-X","article-title":"Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study","volume":"9","author":"Nathan","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2026031709571826700_AnnalsATS.202502-AnnalsATS.202502-148OC-B34","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2022-001310","article-title":"Study design and rationale for the TETON phase 3, randomised, controlled clinical trials of inhaled treprostinil in the treatment of idiopathic pulmonary fibrosis","volume":"9","author":"Nathan","year":"2022","journal-title":"BMJ Open Respir Res"},{"key":"2026031709571826700_AnnalsATS.202502-AnnalsATS.202502-148OC-B35","doi-asserted-by":"publisher","first-page":"e12127","DOI":"10.1002\/pul2.12127","article-title":"Clinical significance of pulmonary hypertension in interstitial lung disease: a consensus statement from the pulmonary vascular research institute\u2019s innovative drug development initiative-Group 3 pulmonary hypertension","volume":"12","author":"Nikkho","year":"2022","journal-title":"Pulm Circ"},{"key":"2026031709571826700_AnnalsATS.202502-AnnalsATS.202502-148OC-B36","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02414-2022","article-title":"Long-term inhaled treprostinil for pulmonary hypertension due to interstitial lung disease: INCREASE open-label extension study","volume":"61","author":"Waxman","year":"2023","journal-title":"Eur Respir J"},{"key":"2026031709571826700_AnnalsATS.202502-AnnalsATS.202502-148OC-B37","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.resinv.2020.12.010","article-title":"Impact of post-capillary pulmonary hypertension on mortality in interstitial lung disease","volume":"59","author":"Teramachi","year":"2021","journal-title":"Respir Investig"},{"key":"2026031709571826700_AnnalsATS.202502-AnnalsATS.202502-148OC-B38","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1161\/01.cir.94.3.477","article-title":"Acute hemodynamic responses to inhaled nitric oxide in patients with limited scleroderma and isolated pulmonary hypertension","volume":"94","author":"Williamson","year":"1996","journal-title":"Circulation"},{"key":"2026031709571826700_AnnalsATS.202502-AnnalsATS.202502-148OC-B39","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s10067-011-1792-4","article-title":"Reactivity of pulmonary circulation and right ventricle function to inhaled nitric oxide in systemic sclerosis patients","volume":"31","author":"Plazak","year":"2012","journal-title":"Clin Rheumatol"},{"key":"2026031709571826700_AnnalsATS.202502-AnnalsATS.202502-148OC-B40","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1378\/chest.12-1594","article-title":"Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction","volume":"143","author":"Han","year":"2013","journal-title":"Chest"},{"key":"2026031709571826700_AnnalsATS.202502-AnnalsATS.202502-148OC-B41","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1111\/resp.12294","article-title":"Haemodynamic changes in pulmonary hypertension in patients with interstitial lung disease treated with PDE-5 inhibitors","volume":"19","author":"Zimmermann","year":"2014","journal-title":"Respirology"}],"container-title":["Annals of the American Thoracic Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/annalsats\/advance-article-pdf\/doi\/10.1513\/AnnalsATS.202502-148OC\/66545221\/annalsats.202502-148oc.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/23\/3\/345\/66545221\/annalsats.202502-148oc.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/23\/3\/345\/66545221\/annalsats.202502-148oc.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T13:57:23Z","timestamp":1773755843000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/annalsats\/article\/23\/3\/345\/8438725"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,15]]},"references-count":41,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,10,15]]},"published-print":{"date-parts":[[2026,3,1]]}},"URL":"https:\/\/doi.org\/10.1513\/annalsats.202502-148oc","relation":{},"ISSN":["2329-6933","2325-6621"],"issn-type":[{"value":"2329-6933","type":"print"},{"value":"2325-6621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2025,10,15]]},"assertion":[{"value":"2025-02-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}